Clinical Trials Browser

Phase 3 × Genetic Testing × 90 days × Clear all

NCT06058377 2026-03-18

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Phase 3 Recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT03233191 2026-03-02

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Phase 3 Active not recruiting

108,508 enrolled

Breast Screening